ArticleInternational journal of microbiology2012
The Lantibiotic Lacticin 3147 Prevents Systemic Spread of Staphylococcus aureus in a Murine Infection Model.
Article in International journal of microbiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Microbe-Derived Antimicrobial Peptides: Immunomodulation and Gut Microbiota Homeostasis.Microorganisms · 2026Review
- In vitro effects of purified lacticin from whey isolatedIranian journal of microbiology · 2025Article
- The Bacteriocins Produced by Lactic Acid Bacteria and the Promising Applications in Promoting Gastrointestinal Health.Foods (Basel, Switzerland) · 2024Review
- Heterologous biosynthesis of myxobacterial lanthipeptides melittapeptins.Applied microbiology and biotechnology · 2024Article
- Inhibition of Clinical MRSA Isolates by Coagulase Negative Staphylococci of Human Origin.Antibiotics (Basel, Switzerland) · 2024Article
- Identification and characterization of antibacterial peptides produced byBioImpacts : BI · 2024Article
- Synthetic and natural antimicrobials as a control against food borne pathogens: A review.Heliyon · 2023Review
- The impact of varying dextran oxidation levels on the inhibitory activity of a bacteriocin loaded injectable hydrogel.Drug delivery and translational research · 2023Article
- Diversity of Bacterial Secondary Metabolite Biosynthetic Gene Clusters in Three Vietnamese Sponges.Marine drugs · 2022Article
- Identification of a Novel Two-Peptide Lantibiotic from Vagococcus fluvialis.Microbiology spectrum · 2022Article
- Alternatives to Fight Vancomycin-ResistantAntibiotics (Basel, Switzerland) · 2021Review
- Therapeutic Application of Lantibiotics and Other Lanthipeptides: Old and New Findings.Applied and environmental microbiology · 2021Review
- Lactic acid bacteria that activate immune gene expression in Caenorhabditis elegans can antagonise Campylobacter jejuni infection in nematodes, chickens and mice.BMC microbiology · 2021Article
- Review
- Recipe for Success: Suggestions and Recommendations for the Isolation and Characterisation of Bacteriocins.International journal of microbiology · 2021Review
- Bioengineered Nisin Derivative M17Q Has Enhanced Activity againstAntibiotics (Basel, Switzerland) · 2020Article
- Bacteriocins From LAB and Other Alternative Approaches for the Control ofFrontiers in bioengineering and biotechnology · 2020Review
- Pharmacological, Toxicological, and Dose Range Assessment of OG716, a Novel Lantibiotic for the Treatment ofAntimicrobial agents and chemotherapy · 2019Article
- A Review: The Fate of Bacteriocins in the Human Gastro-Intestinal Tract: Do They Cross the Gut-Blood Barrier?Frontiers in microbiology · 2018Review
- OG716: Designing a fit-for-purpose lantibiotic for the treatment of Clostridium difficile infections.PloS one · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this study was to investigate the in vivo activity of the lantibiotic lacticin 3147 against the luminescent Staphylococcus aureus strain Xen 29 using a murine model. Female BALB/c mice (7 weeks old, 17 g) were divided into groups (n = 5) and infected with the Xen 29 strain via the intraperitoneal route at a dose of 1 × 10(6) cfu/animal. After 1.5 hr, the animals were treated subcutaneously with doses of phosphate-buffered saline (PBS; negative control) or lacticin 3147. Luminescent imaging was carried 3 and 5 hours postinfection. Mice were then sacrificed, and the levels of S. aureus Xen 29 in the liver, spleen, and kidneys were quantified. Notably, photoluminescence and culture-based analysis both revealed that lacticin 3147 successfully controlled the systemic spread of S. aureus in mice thus indicating that lacticin 3147 has potential as a chemotherapeutic agent for in vivo applications.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.